The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 7, 2002, Pages 569-576

  Howard, Patricia A ^a   Ellerbeck, Edward F ^a   Engelman, Kimberly K ^a   Patterson, Kelly L ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Kansas Foundation for Medical Care   (United States)

Author keywords

Atrial fibrillation; Bleeding; Drug interactions; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CEPHALOSPORIN DERIVATIVE; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; GASTROINTESTINAL AGENT; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MICONAZOLE; PENICILLIN DERIVATIVE; PROPAFENONE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ANTIINFECTIVE AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATIENT COUNSELING; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; AGED; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; FEMALE; HEMOSTASIS; INTERNATIONAL NORMALIZED RATIO; MALE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HEMOSTASIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; WARFARIN;

EID: 0036807539     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.748     Document Type: Article

References (54)

1. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997; 17: 917-928.
2. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 110: S194-S206.
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
5. EAFT (Eurospean Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
6. Feinberg WM, Blackshear JL, Laupacia A. Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469-473.
7. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231-1233.
8. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin. Arch Intern Med 2000; 160: 41-46.
9. Wilson PWF, Benjamin EJ, Manolio TA, et al. Workshop on nonvalvular atrial fibrillation in the elderly: challenges for prevention and care. Am J Ger Cardiol 2000; 9(Suppl.): 73-75.
10. Coumadin Product Information. DuPont Pharma, Wilmington, DE, January 2001.
11. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Safety 1994; 10: 381-394.
12. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983; 25: 610-620.
13. Cannegieter SC, Rosendaal FR, Wintzen AR, van-der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
14. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
15. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-311.
16. Drug Facts and Comparisons 55th Edition. Facts and Comparisons. A Wolters Kluwer Company: St. Louis, MO, 2001.
17. Managing drug interactions of Coumadin (warfarin sodium). CoumaCare. DuPont Pharmaceuticals: Wilmington, DE, 1997.
18. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945-1953.
19. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-683.
20. Howard PA, Dunn MI. Update on drug interactions: warfarin and anti-infective agents. J Respir Dis 1998; 19: 1037-1046.
21. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984; 144: 2413-2414.
22. Schwartz JI, Bachmann KA. Erythromycin-warfarin interaction (letter). Arch Intern Med 1984; 144: 2094.
23. Recker MW, Kier KL. Potential interaction between clarithromycin and warfarin. Ann Pharmacother 1997; 31: 996-998.
24. Gooderham MJ, Bolli P, Fernandez PG. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann Pharmacother 1999; 33: 796-799.
25. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996; 37(Suppl. C): 133-142.
26. Renzi R, Finkbeiner S. Ciprofloxacin interaction with sodium warfarin: a potentially dangerous side effect. Am J Emerg Med 1991; 9: 551-552.
27. Kamada AK. Possible interaction between ciprofloxacin and warfarin. DICP 1990; 24: 27-28.
28. Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy 1992; 12: 435-439.
29. Davey PG. Overview of drug interactions with the quinolones. J Antimicrob Chemother 1988; 22(Suppl. C): 97-107.
30. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000; 63: 28-31.
31. O'Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med 1979; 91: 34-36.
32. Kaufman JM, Fauver HE, Jr. Potentiation of warfarin by trimethoprim-sulfamethoxazole. Urology 1980; 16: 601-603.
33. Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M. The incidence, magnitude and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988; 148: 1779-1781.
34. Hamer A, Peter T, Mandel WJ, Scheinman MM, Weiss D. The potentiation of warfarin anticoagulation by amiodarone. Circulation 1982; 65: 1025-1029.
35. Marcus FI. Drug interactions with amiodarone. Am Heart J 1983; 106: 924.
36. Niopas I, Toon S, Aarons L, Rowland M. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. Eur J Clin Pharmacol 1999; 55: 399-404.
37. Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509-512.
38. Ahmad S. Lovastatin-warfarin interaction. Arch Intern Med 1990; 150: 2407.
39. Rindone JP, Keng HC. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest 1998; 114: 641-642.
40. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs. Chest 2001; 119: S39-S63.
41. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980; 99: 746-751.
42. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart-valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-1541.
43. Turpie AG, Gent M, Laupacis A, et al. Aspirin and warfarin after heart-valve replacement: a comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524-529.
44. Medical Research Council Group. Assessment of short-term anticoagulant administration after cardiac infarction: report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis. BMJ 1969; 1: 335-342.
45. Coumadin, Aspirin Reinfarction Study (CARS) Investigators. Randomized, double-blind trial of fixed low dose warfarin plus aspirin after myocardial infarction. Lancet 1997; 350: 389-396.
46. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998; 98: 1064-1070.
47. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable angina and non-Q-wave infarction in non-prior aspirin users. Primary endpoint analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89: 81-88.
48. Chan TYK. Adverse interactions between warfarin and nonsteroidal anti-inflammatory drugs: mechanisms, clinical significance and avoidance. Ann Pharmacother 1995; 29: 1274-1283.
49. Quick AJ, Clesceri L. Influence of acetylsalicylic acid and salicylamide on the coagulation of blood. J Pharmacol Exp Ther 1960; 128: 95-98.
50. Mackichan JJ. Protein binding drug disposition interactions-fact or fiction? Clin Pharmacokinet 1989; 16: 65-73.
51. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-1671.
52. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 2001; 119: S8-S21.
53. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119: S22-S38.
54. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997; 17: 917-928.